Position
Squarepoint Ops LLC in Amylyx Pharmaceuticals, Inc.
Back to the book · All holders of AMLX
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $139.3K$12.08 → $13.90
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 76.6K | $924.9K | — | — | — | 0.0% |
| Q1 2026 | 114.9K | $1.6M | $13.90 | $139.3K | $532.6K | 0.0% |